Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 12/09/20 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 09/16/20 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 03/03/20 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 03/03/20 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 03/03/20 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 02/13/20 | 5 | Annual statement of changes in beneficial ownership of securities |
|
2 | |
| 02/13/20 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 10/31/19 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 10/30/19 | 4 | Statement of changes in beneficial ownership of securities |
|
3 | |
| 10/30/19 | 4 | Statement of changes in beneficial ownership of securities |
|
2 |
